1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Competitor Analysis: Anti-Obesity Peptides and Biologics

Product description

The present Competitive Intelligence Report about Anti-Obesity Peptides and Biologics used to treat obesity and metabolic syndrome provides a competitor evaluation in the field of R&D projects with anti-obesity peptides and biologics as of February 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. The database also contains information about discontinued projects. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of current active projects in research and development of anti-obesity peptides and biologics such as proteins, antibodies, vaccines, cells, and RNA. In addition, the report lists company-specific R&D pipelines of anti-obesity peptides and biologics. Competitor projects are listed in a tabular format providing information on:
-Drug Codes,
-Target / Mechanism of Action,
-Class of Compound,
-Company,
-Product Category,
-Indication,
-R&D Stage and
-additional comments with a hyperlink leading to the source of information. 

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. 

Table Of Contents

Competitor Analysis: Anti-Obesity Peptides and Biologics
Table of Contents

--Obesity Peptides
-Anti-Obesity Biologics
-Corporate RandD Pipelines of Anti-Obesity Peptides and Biologics
-About La Merie

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Biosimilars and Follow-On Biologics’ Trends, R&D and Revenue Forecasts 2016-2026: Assess Prospects for MAbs, Fusion Proteins, Insulin, G-CSF, Erythropoietin, Interferons, Growth and Fertility Hormones

Biosimilars and Follow-On Biologics’ Trends, R&D and Revenue Forecasts 2016-2026: Assess Prospects for MAbs, Fusion Proteins, Insulin, G-CSF, Erythropoietin, Interferons, Growth and Fertility Hormones

  • $ 7 019
  • Industry report
  • February 2016
  • by Visiongain

Report Details Biosimilars – Discover Revenue Predictions from 2016, Benefiting Your Authority Do you want to find sales potentials of biosimilar drugs? If so, our new analysis gives you revenue forecasts ...

Vaccine Sales Analysis 2016-2026: Discover Trends, R&D and Revenue Forecasts for Protecting Children, Adults and Elderly People from Diseases

Vaccine Sales Analysis 2016-2026: Discover Trends, R&D and Revenue Forecasts for Protecting Children, Adults and Elderly People from Diseases

  • $ 2 807
  • Industry report
  • March 2016
  • by Visiongain

Report Details Vaccines – Your 2016 Guide to Developments, Opportunities and Revenues What does the future hold for vaccine sales? Visiongain’s updated report shows you forecasted sales at overall ...

Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials

Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials

  • $ 1 995
  • Industry report
  • March 2016
  • by Currentpartnering

The Global Cancer Monoclonal Antibody Partnering 2010-2016: Deal trends, players, financials and forecasts report provides an understanding and access to the cancer monoclonal antibody partnering deals ...


ref:plp2012

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.